Tags

Type your tag names separated by a space and hit enter

Cannabidiol in low back pain: scientific rationale for clinical trials in low back pain.
Expert Rev Clin Pharmacol. 2021 Jun; 14(6):671-675.ER

Abstract

INTRODUCTION

The pooled worldwide prevalence of low-back pain-related presentations in primary care varies between 6.8% and 28.4% in the high-income countries rendering it a major healthcare/economy problem. To best manage this complex bio-psycho-social condition a 360-degree approach is needed, as the psycho-social components are often more important than the scant pathophysiology. Pattern analysis of cannabis users suggested that attempts to alleviate musculo-skeletal pain is often seen as a major drive to use cannabinoids.

AREAS COVERED

Unlike NSAIDs/opioids, cannabidiol might directly affect more than one modality of pain signaling/perception. The 2019 guideline of the National Institute for Clinical Excellence recommended further studies with cannabidiol in pain medicine because of its excellent safety profile and presumed therapeutic potential. Therefore, we have researched relevant databases for pharmaco-physiological papers published between 2000 and 2021 to collate evidence in a narrative fashion to determine the clinical rationale for this cannabinoid in low-back pain.

EXPERT OPINION

Observational research reported good results with CBD in pain and fear reduction, which are both key factors in low-back pain. Given the paucity of high-quality evidence, further research is needed to determine the efficacy/non-inferiority of CBD in primary/emergency care setting, using multimodal assessment of various patient-reported outcomes.

Authors+Show Affiliations

University Emergency Department, University of Pecs, Clinical Centre, Hungary.School of Medicine, Cardiff University, Cardiff, United Kingdom of Great Britain and Northern Ireland.Dalhouis University, Hamilton, Canada.Epiconsult Biomedical Agency, Delaware, USA.Alumnus at Semmelweis University Budapest, Hungary.School of Medicine, Cardiff University, Cardiff, United Kingdom of Great Britain and Northern Ireland.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

33861675

Citation

Xantus, Gabor, et al. "Cannabidiol in Low Back Pain: Scientific Rationale for Clinical Trials in Low Back Pain." Expert Review of Clinical Pharmacology, vol. 14, no. 6, 2021, pp. 671-675.
Xantus G, Zavori L, Matheson C, et al. Cannabidiol in low back pain: scientific rationale for clinical trials in low back pain. Expert Rev Clin Pharmacol. 2021;14(6):671-675.
Xantus, G., Zavori, L., Matheson, C., Gyarmathy, V. A., Fazekas, L. M., & Kanizsai, P. (2021). Cannabidiol in low back pain: scientific rationale for clinical trials in low back pain. Expert Review of Clinical Pharmacology, 14(6), 671-675. https://doi.org/10.1080/17512433.2021.1917379
Xantus G, et al. Cannabidiol in Low Back Pain: Scientific Rationale for Clinical Trials in Low Back Pain. Expert Rev Clin Pharmacol. 2021;14(6):671-675. PubMed PMID: 33861675.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cannabidiol in low back pain: scientific rationale for clinical trials in low back pain. AU - Xantus,Gabor, AU - Zavori,Laszlo, AU - Matheson,Candice, AU - Gyarmathy,V Anna, AU - Fazekas,Laszlo M, AU - Kanizsai,Peter, Y1 - 2021/04/28/ PY - 2021/4/17/pubmed PY - 2021/6/17/medline PY - 2021/4/16/entrez KW - CBD KW - Cannabidiol KW - bedriol KW - emergency medicine KW - epidiolex KW - fear reduction KW - low-back pain KW - nabiximols KW - pain reduction KW - primary care setting SP - 671 EP - 675 JF - Expert review of clinical pharmacology JO - Expert Rev Clin Pharmacol VL - 14 IS - 6 N2 - INTRODUCTION: The pooled worldwide prevalence of low-back pain-related presentations in primary care varies between 6.8% and 28.4% in the high-income countries rendering it a major healthcare/economy problem. To best manage this complex bio-psycho-social condition a 360-degree approach is needed, as the psycho-social components are often more important than the scant pathophysiology. Pattern analysis of cannabis users suggested that attempts to alleviate musculo-skeletal pain is often seen as a major drive to use cannabinoids. AREAS COVERED: Unlike NSAIDs/opioids, cannabidiol might directly affect more than one modality of pain signaling/perception. The 2019 guideline of the National Institute for Clinical Excellence recommended further studies with cannabidiol in pain medicine because of its excellent safety profile and presumed therapeutic potential. Therefore, we have researched relevant databases for pharmaco-physiological papers published between 2000 and 2021 to collate evidence in a narrative fashion to determine the clinical rationale for this cannabinoid in low-back pain. EXPERT OPINION: Observational research reported good results with CBD in pain and fear reduction, which are both key factors in low-back pain. Given the paucity of high-quality evidence, further research is needed to determine the efficacy/non-inferiority of CBD in primary/emergency care setting, using multimodal assessment of various patient-reported outcomes. SN - 1751-2441 UR - https://www.unboundmedicine.com/medline/citation/33861675/Cannabidiol_in_low_back_pain:_scientific_rationale_for_clinical_trials_in_low_back_pain. L2 - https://www.tandfonline.com/doi/full/10.1080/17512433.2021.1917379 DB - PRIME DP - Unbound Medicine ER -